Ipamorelin history: discovery to today

Ipamorelin is a synthetic pentapeptide designed in the late 1990s at Novo Nordisk's research site in Helsingør, Denmark. The compound was built with one explicit goal: to trigger growth-hormone release at the pituitary without the cortisol and prolactin spikes that plagued older growth-hormone-releasing peptides. That selectivity claim, confirmed in the original 1998 characterisation paper^[1], is still the main reason ipamorelin shows up in online discussions today. What changed between that first paper and the present is mostly regulatory, not scientific. The human trial programme never progressed beyond early pharmacokinetic work, and the compound remains unapproved as a medicine anywhere in the world.

Origins at Novo Nordisk, 1998

Raun and colleagues at Novo Nordisk published the first full characterisation of ipamorelin in the European Journal of Endocrinology in November 1998^[1]. The pentapeptide was built from five amino acids, several of them non-standard: alpha-aminoisobutyric acid (Aib) and two D-amino acid residues that resist normal enzymatic breakdown, which is what gives the molecule an estimated plasma half-life of roughly two hours. The full sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2.

The selectivity finding was the headline. In both rat pituitary-cell assays and in vivo swine experiments, ipamorelin released growth hormone at potency comparable to GHRP-6 but without raising ACTH or cortisol. The authors wrote that ipamorelin did not release ACTH or cortisol at levels significantly different from those observed following GHRH stimulation, even at doses 200-fold higher than required for GH release. Earlier growth-hormone-releasing peptides such as GHRP-2 and GHRP-6 raised both hormones, which raised safety and comfort concerns for human use. Ipamorelin's cleaner profile attracted attention from the field.

Parallel work from Novo Nordisk's pharmacokinetics group, published the same year in Xenobiotica^[2], compared ipamorelin with several related peptidyl GH secretagogues across intravenous and nasal administration routes in rats. Ipamorelin showed a systemic plasma clearance roughly five-fold lower than GHRP-6, with approximately 60 to 80 percent of the dose recovered intact in bile and urine. Nasal bioavailability was estimated at around 20 percent, lower than some related compounds but still of pharmacological interest.

Early human pharmacokinetic work, 1999

A 1999 paper in Pharmaceutical Research by Gobburu and colleagues modelled the pharmacokinetics and pharmacodynamics of ipamorelin in healthy male volunteers across five escalating intravenous infusion rates^[3]. Each dose produced a single growth-hormone release episode, peaking at roughly 40 minutes. The concentration required for half-maximal stimulation was 214 nmol/L, and the maximum GH production rate modelled was 694 mIU/L per hour. Pharmacokinetics were dose-proportional. The two-hour half-life held across the dose range tested.

These were pharmacokinetic characterisation studies, not therapeutic trials. The studies confirmed that ipamorelin produced a GH pulse in humans with the selectivity profile intact. They did not test body composition, sleep, recovery, or any clinical endpoint. They were not designed to do that, and they did not run long enough to describe an adverse-event profile. The 1999 paper is the closest thing to a human-evidence anchor that the ipamorelin literature has, and it is a modest one.

Why the clinical programme stalled

Ipamorelin did not progress to a phase-2 or phase-3 trial for any indication. There is no published therapeutic trial in the peer-reviewed literature. The reasons are mostly structural. Patent runway on a pentapeptide is limited, and the cost of running a full clinical-trial programme is substantial. Recombinant human growth hormone already occupied the approved-medicine space for growth-hormone deficiency, which removed the most obvious therapeutic target. Other growth-hormone-axis approaches were advancing in parallel. Whatever the internal Novo Nordisk calculus was, the practical result is that ipamorelin's human-data picture stopped at early-phase pharmacokinetics and has not meaningfully grown since.

A 2009 study published in the Journal of Pharmacology and Experimental Therapeutics by Venkova and colleagues at the University of Oklahoma explored ipamorelin as a ghrelin-receptor agonist in a rodent model of postoperative ileus^[4]. That preclinical work showed dose-dependent improvement in bowel function following intravenous ipamorelin in rats, framing the compound as potentially useful for gastrointestinal motility. The findings remained in rodent models and did not generate a subsequent human trial.

The WADA prohibition and grey-market emergence

At some point between the late 1990s discovery work and the mid-2010s, ipamorelin moved from a Novo Nordisk research candidate into the grey-market peptide supply chain. It now circulates as a "research chemical" vial with labelling that reads "not for human use" or "for research purposes only." That labelling convention does not legalise human use and does not put the product through pharmaceutical-quality controls. Independent testing of online vials has repeatedly found purity, identity and contamination failures. See the ipamorelin peptide page for the full practical-considerations section.

Ipamorelin sits on the WADA Prohibited List as a growth-hormone secretagogue under section S2, banned both in-competition and out-of-competition for athletes subject to the WADA Code. No marketing authorisation exists anywhere in our coverage area: not from the FDA, the EMA, the MHRA, or any national agency in the EU or EEA.

The FDA compounding review, 2024

The most recent regulatory milestone for ipamorelin in the United States was the October 2024 meeting of the FDA Pharmacy Compounding Advisory Committee, which reviewed ipamorelin's eligibility as a bulk drug substance under section 503A of the Food, Drug and Cosmetic Act. The 503A pathway allows compounding pharmacies to prepare products from bulk drug substances for individual patients under specific conditions. The PCAC advises the FDA on which substances are suitable for that pathway. It does not grant marketing authorisation, and a positive outcome at the committee level would not make ipamorelin an approved medicine. A new-drug application succeeding is a separate and considerably longer process.

Subsequent federal regulatory shifts in early 2026 have been referenced in commentary on the US compounding landscape. The practical status as of mid-2026 is unchanged: ipamorelin is not an approved medicine, and the evidentiary picture that would support a new-drug application has not materially changed since the 1999 pharmacokinetic work.

What we do not yet know

The open questions are large. There is no published therapeutic efficacy trial for ipamorelin in any indication. There is no long-duration human safety dataset. The effects of repeated dosing over weeks or months on glucose handling, IGF-1 trajectory, and cancer risk are uncharacterised. The mechanistic concern that growth-hormone-axis peptides may carry cancer risk is a category-level worry shared with CJC-1295 and tesamorelin; the available evidence does not let us rule it in or out for ipamorelin specifically. If you are considering ipamorelin, that decision belongs with a clinician who knows your history. For jurisdiction-specific status, see the ipamorelin regulation pages.